These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23096413)

  • 21. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
    Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
    J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prime time for molecular marker diagnostics in neuro-oncology.
    Weller M; Stupp R
    Curr Opin Neurol; 2012 Dec; 25(6):743-4. PubMed ID: 23041956
    [No Abstract]   [Full Text] [Related]  

  • 26. Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
    Li S; Zhang W; Chen B; Jiang T; Wang Z
    Neurol Res; 2010 Sep; 32(7):690-4. PubMed ID: 19703338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epilysin is overexpressed in glioblastoma and related to clinical outcome of patients.
    Wang X; Zhang K; Chen X; Zhao C; Sun Z
    Med Oncol; 2015 Jan; 32(1):363. PubMed ID: 25429835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials.
    Merkel A; Soeldner D; Wendl C; Urkan D; Kuramatsu JB; Seliger C; Proescholdt M; Eyupoglu IY; Hau P; Uhl M
    J Neurooncol; 2017 Apr; 132(2):249-254. PubMed ID: 28101701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
    Ohno M; Narita Y; Miyakita Y; Matsushita Y; Arita H; Yonezawa M; Yoshida A; Fukushima S; Takami H; Ichimura K; Shibui S
    Jpn J Clin Oncol; 2016 Jan; 46(1):31-9. PubMed ID: 26603354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Glioblastoma.
    Nam JY; de Groot JF
    J Oncol Pract; 2017 Oct; 13(10):629-638. PubMed ID: 29020535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MGMT methylation in glioblastoma: tale of the tail.
    Shah N; Schroeder B; Cobbs C
    Neuro Oncol; 2015 Jan; 17(1):167-8. PubMed ID: 25395464
    [No Abstract]   [Full Text] [Related]  

  • 34. Extent of resection of peritumoral diffusion tensor imaging-detected abnormality as a predictor of survival in adult glioblastoma patients.
    Yan JL; van der Hoorn A; Larkin TJ; Boonzaier NR; Matys T; Price SJ
    J Neurosurg; 2017 Jan; 126(1):234-241. PubMed ID: 27058207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
    PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma.
    Sørensen MF; Heimisdóttir SB; Sørensen MD; Mellegaard CS; Wohlleben H; Kristensen BW; Beier CP
    J Neurooncol; 2018 May; 138(1):49-53. PubMed ID: 29404978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
    Singh G; Mallick S; Sharma V; Joshi N; Purkait S; Jha P; Sharma MC; Suri V; Julka PK; Mahapatra AK; Singh M; Kale SS; Sarkar C
    Neuropathology; 2012 Oct; 32(5):534-42. PubMed ID: 22380407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glioblastoma in the elderly.
    Chamberlain MC
    Cancer Treat Res; 2015; 163():159-70. PubMed ID: 25468231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebellar glioblastoma multiforme: a retrospective study of 28 patients at a single institution.
    Yang S; Liu J; Wang T; Li X; You C
    Int J Neurosci; 2013 Oct; 123(10):691-7. PubMed ID: 23550813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.